COMMUNIQUÉS West-GlobeNewswire

MEDIROM to Launch New Treasury Strategy Utilizing Cryptocurrency
29/10/2025
Aimed at incentivize large-scale vital data collection TOKYO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc., (Headquarters: Minato-ku, Tokyo; President and CEO: Kouji Eguchi; listed on the [...]
OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category
29/10/2025
Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 [...]
FDA Grants Orphan Drug Designation to Dewpoint Therapeutics’ DPTX3186 for the Treatment of Gastric Cancer
29/10/2025
First orphan designation ever granted to a condensate-modulating therapeutic Builds on recent IND opening for DPTX3186, a first-in-class oral condensate modulator targeting the Wnt/ β -catenin pathway Provides key [...]
Betterguards Launches The BetterGuard Lite, a Powerful New Ankle Protection System with Breakthrough Design
29/10/2025
The BetterGuard Lite features an impossibly thin, lightweight design at an affordable price for athletes worldwide NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Betterguards , a sports technology innovator, today [...]
Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug
29/10/2025
Data from the dose optimization trial expected soon ProLectin-M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the [...]
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
29/10/2025
New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including JAKs [...]
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
29/10/2025
SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum